Comparison of Efficacy of Intravitreal Ranibizumab and Aflibercept in Central Serous Chorioretinopathy

Abstract

Aim: To compare the efficacy of Ranibizumab and Aflibercept in managing Central Serous Chorioretinopathy.

Study Design: Retrospective study.

Duration and Settings of Study: This study was carried out at Bodla eye-care and Department of Ophthalmology at Combined Military Hospital (CMH) Multan on the record of patients having Central Serous Chorioretinopathy (CSCR) with a follow-up period from July 2022 to July 2024.

Methods: This study included 20 eyes of 20 patients with recurrent to chronic CSCR. All patients underwent vision assessment, fundus examination, and Optical Coherence Tomography (OCT) before and after treatment. Ten eyes received Ranibizumab (Patizra) 0.2 ml (2mg) and ten eyes received Aflibercept (Eylea) 0.1 ml (4mg) single injection. The effectiveness was measured by improvements in the Best-Corrected Visual Acuity (BCVA) using Log MAR chart; and reduction in the Central Macular Thickness (CMT) evaluated by OCT.

Results: Initial BCVA for Ranibizumab-treated eyes ranged from 0.2 LogMAR to 1.0 LogMAR, with CMT between 250 and 560 microns. Aflibercept-treated eyes had baseline BCVA from 0.3 LogMAR to 0.7 LogMAR and CMT between 377 and 567 microns. After four to six weeks, BCVA improved to 0.0 LogMAR to 0.6 LogMAR in the Ranibizumab group, with CMT reduced to 198-421 microns. In the Aflibercept group, BCVA improved to 0.0 LogMAR to 0.5 LogMAR, with CMT reduced to 182-367 microns.

Conclusions: Both treatments significantly improved macular health in chronic CSCR patients. However, this study shows that Aflibercept has much better results with the standard dose as compared to Ranibizumab in the management of CSCR.